Project Grant 2213253
Award Date
9/15/22
Completion Date
8/31/23
Dollars Obligated
$256K
Federal Agency
National Science Foundation
Awardee
Vcreate, Inc. (TDGANH2K4J93)
Federal Grant Program
47.084
Assistance Type
Project Grant
Place of Performance
San Carlos, CA 94070, USA
Similar Awards
This $1,008,000 Cooperative Agreement award was granted by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program. The funding supports Vcreate, Inc., a minority-owned small disadvantaged business located in West Menlo Park, California, to develop a high-throughput platform for screening millions of T-cell receptors (TCRs) against a large set of clinically relevant cancer antigens. The objective is to discover and validate promising...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Cerflux Inc. aims to develop a personalized cancer treatment screening platform. The project will establish guidelines for handling solid tumor biopsy samples, generate 3D bioprinted tumor models for validation, and demonstrate the platform's ability to match patients with the most effective cancer treatments before treatment begins. This innovative approach has the...
This National Science Foundation (NSF) Cooperative Agreement award, under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), provides $1,250,000 in funding to Rattan Life Science Inc., a small disadvantaged business located in Sunnyvale, CA, to develop and validate a novel platform technology for the scalable generation of high-quality, tumor-targeted induced naïve T cells for off-the-shelf cancer immunotherapies. The project aims to increase the efficacy of induced...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $305,000 to Redpoint Oncology, Inc. aims to develop and validate a novel platform for targeted cancer therapies. The project will design and synthesize new payload candidates, test their effectiveness and selectivity against therapy-resistant cancer cells, and establish proof-of-concept for this innovative therapeutic approach. The broader impact includes addressing critical unmet...
This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...
This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to develop a method to turn on cancer immunotherapies only at the site of disease. The $275,000 award will support Synsorybio, Inc., a for-profit organization, in creating protein switches that activate immunotherapies in response to disease signals, rather than indiscriminately throughout the body. This approach seeks to improve the...
This SBIR Phase I award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC for the development of a combinatorial platform to discover improved molecular recognition components for use in therapeutic and diagnostic antibodies. The project aims to utilize synthetic biology, next-generation DNA sequencing, and computational biology to efficiently generate and screen libraries of antibody...
This National Science Foundation Project Grant of $255,995 supported Encapsulate Inc. to develop an automated biochip platform for personalized cancer screening under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084). The award period was from May 15, 2022 to April 30, 2023. The platform will grow patient-derived cancer cells outside the body on biochips to screen them against chemotherapy drugs. This addresses the problem that over 70% of cancer patients undergo ineffective...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Technology Transfer (STTR) award of $275,000 provides funding to Vivosphere LLC in Auburn, Alabama to develop a novel tissue-engineered platform for more effective cancer drug screening. The project aims to create a 3D hydrogel scaffold that provides a more physiologically relevant microenvironment for cell growth and drug response, enabling higher-throughput and more predictive...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) grant award of $295,000 to Theracea Pharma LC, a for-profit limited liability company, focuses on developing innovative 18F-radiotracer kits for detecting biomarkers using positron emission tomography (PET). The project aims to create advanced diagnostic tools that will assist researchers and clinicians, particularly in the field of oncology, by enabling more precise selection and assessment of cancer...